Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immunotherapy: a new hope for bone metastatic prostate cancer

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Anchal Mishra

Citation

Annals of Oncology (2015) 26 (suppl_9): 103-106. 10.1093/annonc/mdv528

Authors

A.N. Mishra1, S. Medhashri2

Author affiliations

  • 1 Department Of Orthopaedics, Gandhi Medical College and Hamidia Hospital, 462022 - Bhopal/IN
  • 2 Department Of Pharmacy, Burkatullah University, Bhopal/IN
More

Resources

Aim/Background

Castration-resistant prostate cancer (CRPC) is disease progression despite chemical castration, indicated by rising levels of prostate-specific antigen (PSA). Patients with metastatic castration-resistant prostate cancer (mCRPC) have a poor prognosis with survival rate of less than 2 years. Prostate cancer preferentially metastasizes to bone.As the disease transits from castration sensitive to castration resistant, the incidence of bone metastasis increases, with more than 90% of patients with mCRPC developing bone metastases. Symptomatic patients with mCRPC are at high risk for spontaneous fracture and spinal cord compression, causing significant pain and poor quality of life. A paucity of therapeutic options is available for mCRPC. But, recent developments in our understanding of the disease have resulted in several new therapies that show promise in improving overall survival rates.

Methods

Agents generally use in India and those undergoing clinical trials for the treatment of mCRPC were reviewed. Recent contributions to the understanding of prostate biology and bone metastasis were discussed as well as how the underlying mechanisms may represent opportunities for therapeutic intervention. New drugs with various combinations were tried on 980 patients in last 3years.

Results

New and emerging treatments that target androgen synthesis (Abiraterone acetate), Taxane-derived chemotherapies (Docetaxel & Cabazitaxel) and targeting the genetically stable host microenvironment to make mCRPC more visible to cytotoxic T cells (Sipulecuel-T) improves overall survival rates. Determining how factors derived from the primary tumor can promote the development of premetastatic niches and how prostate cancer cells parasitize niches in the bone microenvironment, thus remaining dormant and protected from systemic therapy, could yield new therapies to treat mCRPC.

Conclusions

The emergence of novel treatments for mCRPC, combined with improved patient stratification and optimized therapy sequencing, suggests that significant gains may be made in terms of overall survival rates for men diagnosed with this form of cancer.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings